

This is an Accepted Manuscript version of the following article, accepted for publication in **XENOBIOTICA**.

Postprint of: Potęga A., Fedejko-Kap, B., Mazerska Z., Mechanism-based inactivation of human cytochrome P450 1A2 and 3A4 isoenzymes by antitumor triazoloacridinone C-1305, *XENOBIOTICA*, Vol. 46, Iss. 12 (2016), pp. 1056-1065, DOI: [10.3109/00498254.2016.1147623](https://doi.org/10.3109/00498254.2016.1147623)

It is deposited under the terms of the Creative Commons Attribution-NonCommercial License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.

## **Title page**

### **Title:**

Mechanism-based inactivation of human cytochrome P450 1A2 and 3A4 isoenzymes by anti-tumour triazoloacridinone C-1305.

### **Authors:**

Agnieszka Potęga, Barbara Fedejko-Kap, Zofia Mazerska.

### **Affiliation:**

Department of Pharmaceutical Technology and Biochemistry (A.P., B.F-K., and Z.M.),  
Chemical Faculty, Gdańsk University of Technology, Gabriela Narutowicza St. 11/12, Gdańsk  
80-233, Poland.

### **Corresponding author:**

Agnieszka Potęga

telephone: +48 58 347 15 93, fax: +48 58 347 11 44, e-mail: [agnieszka.potega@pg.gda.pl](mailto:agnieszka.potega@pg.gda.pl)

**Keywords:** anti-tumour agent, C-1305, human CYP isoenzymes, bioactivation, drug-drug interactions, mechanism-based inactivation

## Abstract

1. 5-Dimethylaminopropylamino-8-hydroxytriazoloacridinone, C-1305, is a promising anti-tumour therapeutic agent with high activity against several experimental tumours.
2. It was determined to be a potent and selective inhibitor of liver microsomal and human recombinant cytochrome P450 (CYP) 1A2 and 3A4 isoenzymes. Therefore, C-1305 might modulate the effectiveness of other drugs used in multidrug therapy.
3. The objective of the present study was to investigate the mechanism of the observed C-1305-mediated inactivation of CYP1A2 and CYP3A4.
4. Our findings indicated that C-1305 produced a time- and concentration-dependent decrease in 7-ethoxycoumarin O-deethylation (CYP1A2,  $K_i = 10.8 \pm 2.14 \mu\text{M}$ ) and testosterone 6 $\beta$ -hydroxylation (CYP3A4,  $K_i = 9.1 \pm 2.82 \mu\text{M}$ ). The inactivation required the presence of NADPH, was unaffected by a nucleophilic trapping agent (glutathione) and a reactive oxygen species scavenger (catalase), attenuated by a CYP-specific substrate (7-ethoxycoumarin or testosterone), and was not reversed by potassium ferricyanide. The estimated partition ratios of 1086 and 197 were calculated for the inactivation of CYP1A2 and CYP3A4, respectively.
5. In conclusion, C-1305 inhibited human recombinant CYP1A2 and CYP3A4 isoenzymes by mechanism-based inactivation. The obtained knowledge about specific interactions between C-1305 and/or its metabolites, and CYP isoforms would be useful for predicting the possible drug-drug interactions in potent multidrug therapy.



## Introduction

5-Dimethylaminopropylamino-8-hydroxytriazoloacridinone, C-1305 (Figure 1), is a representative derivative among triazoloacridinones (TAs), anti-tumour compounds developed at the Gdańsk University of Technology (Cholody et al. 1990a). It is a promising therapeutic agent with high anti-tumour activity against several experimental cellular models and tumours in mice, particularly leukemias and colon carcinomas (Kusnierczyk et al. 1994). The clinical potential of the compound is being currently evaluated in extended preclinical trials. Simultaneously, the extensive studies on the biologic and biochemical mechanisms of C-1305 action have been conducted (Augustin et al. 2006; Fedejko-Kap et al. 2011, 2012).

It was postulated that an ability of C-1305 to bind to cellular DNA by intercalation (Lemke et al. 2005; Koba & Konopa 2007) may be crucial for the molecular mechanism of its anti-tumour activity. Apart from the reversible DNA interaction, it has been also reported that C-1305 induced interstrand DNA crosslinking in tumour cells, which occurred only after metabolic activation (Dziegielewski & Konopa 1996; Koba & Konopa 2007). Another unique mode of action of this TA is the inhibition of the catalytic activity of topoisomerase II by stabilizing the formation of a cleavable complex between DNA and topoisomerase II *in vitro* and in living cells (Skladanowski et al. 1996; Dziegielewski et al. 2002). The above-mentioned features of C-1305 confirm that it should be considered as a valuable anti-tumour drug candidate.

The previous suggestions that the metabolic activation by intracellular enzymes might be a prerequisite for biochemical action of C-1305 on the cellular level (Dziegielewski & Konopa 1996; Koba & Konopa 2007) prompted us to study on the role of drug-metabolizing enzymes in metabolic transformation of this compound (Fedejko-Kap et al. 2011, 2012; Pawlowska et al. 2012). Our recent studies revealed that, contrary to the majority of therapeutic agents, C-1305 and its less active 8-methoxy derivative, C-1299 (Figure 1), were not metabolized by the main cytochrome P450 (CYP) families, CYP1, CYP2 and CYP3. Both C-1305 as well as C-1299 were found to be selective inhibitors of human (unpublished results) and rat liver microsomal, and human recombinant CYP1A2 and CYP3A4 isoenzymes. The determined IC<sub>50</sub> values of C-1305 were 0.95 µM and 3.12 µM, respectively (Fedejko-Kap et al. 2011). The type



and the exact mechanism of the observed inhibition was not assessed then. However, these results indicated that, whereas the substitution of a hydroxyl group at position 8 provides C-1305 high anti-tumour activity, other moieties within TA molecule are presumably responsible for the inactivation of CYP1A2 and CYP3A4 isoenzymes. In contrast, CYP2 family isoforms were not inactivated by C-1305 and C-1299. On the other hand, flavin-containing monooxygenases (FMOs) 1 and 3 were demonstrated to be crucial enzymes metabolizing both compounds in rat and human liver microsomes and in human hepatocellular liver carcinoma cell line (HepG2) cells (Fedejko-Kap et al. 2011). In addition, we showed that C-1305 underwent UDP-glucuronosyltransferase (UGT)-mediated metabolism in human liver and intestinal microsomes to 8-O-glucuronide. The observed glucuronidation was catalysed mainly by UGT1A10 of the UGT1A family, whereas UGT2B family isoforms did not participate in C-1305 metabolism (Fedejko-Kap et al. 2012; Pawlowska et al. 2012).

Considering that C-1305 inhibits the catalytic activity of CYP1A2 and CYP3A4 isoforms, the purpose of the present study was to extensively evaluate the specific interactions between C-1305 and CYP1A2 and CYP3A4 isoenzymes. Among 57 human cytochromes P450, the 1A2 and 3A4 isoforms are two of the most abundant and important, because they metabolize the majority of the administered drugs (Guengerich 1995). A remarkable feature of CYP1A2 and CYP3A4 is the extreme diversity in substrate specificity and cooperative substrate binding, so their activity can be modulated by drugs. Consequently, changes in drug metabolism might result in clinically significant drug-drug interactions, leading to undesirable adverse reactions or therapeutic failures. Such interactions involving, e.g., warfarin, antidepressants, anti-epileptic drugs, and statins, often relate to changes in CYPs' activity (Kivisto et al. 1995; Guengerich 1999; Bibi 2008). Knowledge about the ability of drugs to be metabolized by cytochrome P450 isoenzymes and about their influence on the activity of enzymes can help to minimize the possibility of adverse drug reactions and interactions. C-1305, being a potent inhibitor of CYP1A2 and CYP3A4, might modulate the effectiveness of other drugs used in multidrug therapy. Among drugs that cause clinically significant pharmacokinetic drug-drug interactions, mechanism-based inactivators of cytochromes P450 represent several of those



agents that cause interactions of the greatest magnitude (Venkatakrisnan et al. 2007). It has previously been confirmed for a number of drugs with a triazole moiety (Grimm & Dyroff 1997; Stresser et al. 2004) or with a diaminoalkyl side chain (Murray & Murray 2003; Kalgutkar et al. 2007). Both functional groups are also present in the C-1305 molecule. It was believed that they formed a reactive intermediate that could irreversibly modify critical active site moieties and thus inactivate the enzyme in a process characterized as mechanism-based inactivation, MBI (Kalgutkar et al. 2007). In view of this fact we expected that such interactions between C-1305 and CYPs may also occur.

Therefore, the current study was designed to determine whether C-1305 is a mechanism-based inactivator of CYP1A2 and CYP3A4 isoforms. A kinetic study of CYPs' inactivation by C-1305 was carried out. The inactivation experiments, which involved a 10-fold dilution step, were performed *in vitro* using the human recombinant CYP1A2 and CYP3A4 (Bactosomes). CYP isoenzyme activities were determined using the CYP-specific reactions, 7-ethoxycoumarin O-deethylation (CYP1A2) (Yamazaki et al. 1996) and testosterone 6 $\beta$ -hydroxylation (CYP3A4) (Yuan et al. 2002). The concentrations of CYP-specific substrates and their metabolites formed by CYP isoenzymes were measured by reversed-phase high performance liquid chromatography (RP-HPLC) with UV-Vis and/or diode array and multiple wavelength detection. The elucidation of the mechanism of C-1305-mediated inactivation of CYP1A2 and CYP3A4 may provide new insights into the role of C-1305-CYP interactions in the anti-tumour action of this drug, particularly considering that the metabolism of C-1305 by CYPs was not observed. This knowledge would be applied to predict the possible drug-drug interactions induced by this agent in potent multidrug therapy.



**List of abbreviations:**

**CAT**, catalase;

**CYP**, cytochrome P450;

**C-1305**, 5-dimethylaminopropylamino-8-hydroxytriazoloacridinone;

**7EC**, 7-ethoxycoumarin;

$t_{1/2inact}$ , inactivation half-life;

**MBI**, mechanism-based inactivation;

**NADPH**,  $\beta$ -nicotinamide adenine dinucleotide phosphate, tetrasodium salt;

**P**, partition ratio of inactivation;

**RP-HPLC**, reversed-phase high performance liquid chromatography;

**TT**, testosterone;

**$K_i$** , the concentration required for half-maximum inactivation;

**$k_{inact}$** , the maximum rate of inactivation at saturation;

**$k_{obs}$** , the observed inactivation rate constant;

**TA**, triazoloacridinone;

## **Materials and methods**

### ***Chemicals and reagents***

A triazoloacridinone derivative C-1305 was synthesized as hydrochloride in the Department of Pharmaceutical Technology and Biochemistry, Gdańsk University of Technology (Gdańsk, Poland), as described earlier (Cholody et al. 1990a). 7-Ethoxycoumarin (7EC), formic acid, L-glutathione reduced (GSH), potassium ferricyanide, and testosterone (TT) were purchased from Sigma-Aldrich Co. (St. Louis, MO). Methanol (gradient grade for liquid chromatography) and  $\beta$ -nicotinamide adenine dinucleotide phosphate, tetrasodium salt (NADPH) were obtained from Merck KGaA (Darmstadt, Germany). Ammonium formate was from Fisher Scientific (Loughborough, UK). All other commercially available chemicals and solvents were of the highest purity available. Redistilled water ( $R > 18 \text{ M} \cdot \text{cm}$ ) was used to prepare all the solutions.

Stock solutions of C-1305 (2 and 4 mM) and NADPH (20 mM) were freshly prepared in filter sterilized 0.1 M potassium phosphate (pH 7.4 buffer solution). 7EC (20 mM) and TT (20 mM) were prepared in DMSO, and then diluted 10-fold with water for each experiment. GSH (10 mM) and potassium ferricyanide (20 mM) were freshly prepared in water. To obtain 0.1 M potassium phosphate (pH 7.4 buffer solution) 0.1 M monobasic potassium phosphate and 0.1 M dibasic potassium phosphate were mixed, and the correct pH was adjusted by adding 1 N potassium hydroxide.

### ***Enzymes***

The human recombinant cytochrome P450 (CYP) isoenzymes: 1A2 (10.5  $\mu\text{M}$  stock solution in Bactosome storage buffer, 50 mM Tris acetate pH 7.6, 250 mM sucrose, 0.25 mM EDTA) and 3A4 (7.2  $\mu\text{M}$  stock solution in Bactosome storage buffer), co-expressed with human NADPH-cytochrome P450 oxidoreductase (POR) in *Escherichia coli* cells (Bactosomes), were purchased from Tebu-bio (Le Perray-En-Yvelines, France). Catalase from bovine liver (20000 U/mL stock solution in water) was obtained from Sigma-Aldrich Co. (St. Louis, MO).

### ***Instrumentation (HPLC analysis)***



The concentrations of CYP-specific substrates (7EC or TT) and their metabolites, formed in Bactosomes 1A2 or 3A4, were measured by RP-HPLC with UV-Vis detection and/or diode array and multiple wavelength detection. The supernatants, obtained according to the procedures described below, were analysed with a reversed-phase 5- $\mu$ m Suplex pKb-100 analytical column (0.46 cm x 25 cm, C18) (Supelco Inc., Bellefonte, PA) with Waters Associates HPLC systems (Waters Co., Milford, MA). One Waters HPLC system was equipped with a model 600E system controller, a model 7725i Rheodyne injector, and a model 2996 photodiode array detector (DAD) controlled with Millennium software. The second Waters HPLC system contained: a model 1525 binary HPLC pump, a model 7725i Rheodyne injector, a model 2487 dual  $\lambda$  absorbance detector, and a model 717 plus autosampler controlled with Breeze software. The HPLC analyses were carried out at a flow rate of 1 mL/min with the following mobile phase system: a linear gradient from 15% to 80% methanol in ammonium formate (0.05 M, pH 3.4) for 25 min, followed by a linear gradient from 80% to 100% methanol in ammonium formate for 3 min. The eluates were monitored at 324 nm and 245 nm for 7ET and TT, respectively.

### ***Enzyme inactivation assays***

The activities of CYP isoenzymes were determined by measuring the rate of the CYP-specific reactions, 7-ethoxycoumarin O-deethylation (CYP1A2) and testosterone 6 $\beta$ -hydroxylation (CYP3A4) (Yamazaki et al. 1996; Yuan et al. 2002).

The method used for the inactivation experiments involved two steps: a primary (preincubation) reaction with the inhibitor and a secondary (incubation) reaction with the substrate, with these two steps conducted in separation reaction tubes, all presented in Figure 2. Primary reaction mixture containing potassium phosphate buffer (0.1 M, pH 7.4), CYP1A2 or CYP3A4 (0.5  $\mu$ M), and increasing concentrations of C-1305 (0, 5, 10, 25, 50, and 100  $\mu$ M) was pre-warmed for 3 min at 37°C in a shaking water bath. Enzymatic reaction was initiated by adding NADPH (0.5 mM), which was excluded in negative control incubations, and preincubated for varying lengths of time (as specified in the figure legends). Subsequently, an aliquot (10  $\mu$ L) of the primary reaction mixture was periodically transferred to 90  $\mu$ L of pre-





warmed (for 3 min at 37°C) secondary incubation mixture (total volume of 100 µL) containing potassium phosphate buffer, 7EC or TT (20 µM), and NADPH (0.5 mM). CYP-specific substrates were added from 2 mM stock solutions in 10% DMSO (the final concentration of DMSO in the incubation mixture was 0.1%). The enzymatic reaction in the secondary incubation mixture was incubated for 30 min at 37°C and terminated by adding of ice-cold methanol (1:1, v/v). The incubation mixture was placed in ice for 10 min and then centrifuged for 5 min at 12 000g. An aliquot of the supernatant (100 µL) was then analyzed directly by RP-HPLC to establish remaining enzyme activity.

The 10-fold dilution of the primary reaction mixture allowed differentiation of covalent (irreversible) inactivation from competitive inhibition by C-1305. Results representative of at least three independent experiments were considered. The calculation of kinetic constants, which describe mechanism-based enzyme inactivators, was performed as described previously (Kitz & Wilson 1962; Hollenberg et al. 2008). Briefly, the relative inhibition of 7-hydroxycoumarin or 6β-hydroxytestosterone formation were determined by comparing peak area ratios of time-matched samples with C-1305 versus control samples without C-1305. These natural logarithm of relative inhibition values were plotted versus preincubation time for each concentration of C-1305 used, and the slopes were obtained by linear regression (GraphPad Prism 6.05; GraphPad Software, Inc., San Diego, CA). These slopes represent the observed inactivation rate constants ( $k_{obs}$ ), which were used to calculate the half-life of the inactivation reaction. A Kitz-Wilson plot was then constructed using the calculated half-life values ( $y$ -axis) and the reciprocal of the associated C-1305 concentration ( $x$ -axis). The apparent  $K_i$  (the concentration required for half-maximum inactivation) and  $k_{inact}$  (the maximum rate of inactivation at saturation) values were determined from the reciprocal of the  $y$ -axis intercept and the negative reciprocal of the  $x$ -axis intercept of the Kitz-Wilson plot, respectively. The time required for half of the enzyme molecules to be inactivated ( $t_{1/2}$ ) was determined by the equation:

$$t_{1/2} = \ln 2 / k_{inact}$$

#### ***Effects of a competing CYP-specific substrate***



The inactivation of CYP1A2 or CYP3A4 (0.5  $\mu\text{M}$ ) by C-1305 (20  $\mu\text{M}$ ) in the absence and presence of a CYP-specific substrate was investigated by adding a 2- and 4-fold molar excess of 7-ethoxycoumarin or testosterone, respectively, over C-1305 to the primary reaction mixture. At the end of the incubation time, aliquots (10  $\mu\text{L}$ ) of the primary reaction mixtures in triplicate were periodically removed and assayed for remaining enzyme activity in a secondary incubation mixture as described above.

#### ***Effects of exogenous nucleophilic trapping agent (GSH) and scavenger of reactive oxygen species (catalase)***

GSH (1, 2, and 5 mM) was included in the primary reaction mixture with CYP1A2 or CYP3A4 (0.5  $\mu\text{M}$ ), C-1305 (20  $\mu\text{M}$ ), and NADPH (0.5 mM). Aliquots (10  $\mu\text{L}$ ) of the primary reaction mixtures in triplicate were periodically removed to estimate the remaining enzyme activity in a secondary incubation mixture as described above. In control samples, potassium phosphate buffer was added in place of GSH. In a separate study, CYP1A2 or CYP3A4 was incubated with C-1305 and NADPH in the absence and presence of catalase (1000 and 2000 U/mL).

#### ***Effects of potassium ferricyanide (irreversibility of inactivation)***

The experiment was divided into three parts: the inactivation assay (preincubation), the restoration of activity assay, and the remaining activity assay. Primary reaction mixture containing potassium phosphate buffer, CYP1A2 or CYP3A4 (0.5  $\mu\text{M}$ ), C-1305 (20  $\mu\text{M}$ ), and NADPH (0.5 mM) was preincubated for 30 min at 37°C in a shaking water bath. Negative control incubations lacked NADPH. An aliquot (10  $\mu\text{L}$ ) of the primary reaction mixture in triplicate was periodically removed and added to the restoration of activity plate, which had 50  $\mu\text{L}$  of the potassium ferricyanide (2 mM; potassium phosphate buffer for the controls). After a further 15-min incubation, another 10- $\mu\text{L}$  aliquot was taken and assayed for the determination of the remaining CYP1A2 and CYP3A4 activity in a secondary incubation mixture as described above.

#### ***Partition ratio determination***



Primary reaction and secondary reaction mixtures were prepared similarly to those reported in the section on enzyme inactivation assays. In this experiment, incubations were conducted at various concentrations of C-1305 (0-2.5 mM) for 30 min to ensure complete inactivation. Negative control incubations lacked NADPH. Aliquots (10  $\mu$ L) of the primary reaction mixtures were periodically removed and assayed for remaining enzyme activity in a secondary incubation mixture as described above. The percentage remaining enzyme activity was plotted versus the ratio [C-1305]/[CYP]. As previously described (Silverman 1996; Kent et al. 1998), extrapolating the intercept of the linear regression of lower C-1305 concentrations and the horizontal line from saturating C-1305 concentrations yielded the partition ratio of inactivation (P).

### ***Statistical analysis***

All of the data reported represent the mean  $\pm$  standard deviation (SD). Statistical evaluation was performed using GraphPad Prism 6.05 (GraphPad Software, Inc., San Diego, CA) and employed an unpaired *t*-test or a two-way analysis of variance (ANOVA) followed by Bonferroni's multiple comparisons test, and  $p < 0.05$  was accepted to be statistically significant.

## Results

### ***Kinetics of the inactivation of human recombinant CYP1A2 and CYP3A4 by C-1305***

Time-dependent enzyme inhibition is the primary criterion to determine irreversible or mechanism-based inhibitors (Kalgutkar et al. 2007). To characterize in detail the kinetics of CYP1A2 and CYP3A4 inactivation, varying concentrations of C-1305 were preincubated with human recombinant CYP isoform and NADPH at 37°C for varying lengths of time. As shown in Figure 3, both 7-ethoxycoumarin O-deethylation as well as testosterone 6 $\beta$ -hydroxylation declined in a time- and concentration-dependent manner when CYP isoform was preincubated with C-1305 in the presence of NADPH for up to 60 min. Enzyme kinetic analyses of CYPs' inactivation by C-1305 were conducted by the Kitz-Wilson plot (Figure 3, the insets). With this method, we estimated the maximum rates of inactivation at saturation ( $k_{inact}$ ) of 0.016 min<sup>-1</sup> (CYP1A2) and 0.022 min<sup>-1</sup> (CYP3A4). The concentrations of C-1305 required to produce half-maximum CYP inactivation ( $K_i$ ) were 10.8 $\pm$ 2.14  $\mu$ M (CYP1A2) and 9.1 $\pm$ 2.82  $\mu$ M (CYP3A4). The times required for half of the enzymes to be inactivated ( $t_{1/2inact}$ ) were 43.3 min (CYP1A2) and 31.5 min (CYP3A4). Hence, the ratio of  $k_{inact}$  to  $K_i$ , which is used to assess the efficiency of enzyme inactivation (Kalgutkar et al. 2007), was 0.0015 min<sup>-1</sup> $\mu$ M<sup>-1</sup> (CYP1A2) and 0.0024 min<sup>-1</sup> $\mu$ M<sup>-1</sup> (CYP3A4). The values of all kinetic parameters are presented in Table 1.

### ***NADPH-dependent inactivation of human recombinant CYP1A2 and CYP3A4 by C-1305***

To assess whether the inactivation of CYP1A2 and CYP3A4 by C-1305 required NADPH, we performed experiments in which varying concentrations of C-1305 were preincubated with human recombinant CYP isoform at 37°C for 60 min in the presence or absence of NADPH. The remaining CYP1A2 activity in samples co-incubated with C-1305 and 1 mM NADPH was 23 $\pm$ 2.8% and 20 $\pm$ 1.3% lower at C-1305 concentrations of 5 and 100  $\mu$ M, respectively, compared to NADPH-free incubations (Figure 4A). The remaining CYP3A4 activity in samples that had C-1305 co-incubated with 1 mM NADPH decreased 26 $\pm$ 1.9% and 19 $\pm$ 2.4% at C-1305 concentrations of 5 and 100  $\mu$ M, respectively, compared to samples that lacked NADPH (Figure 4B). Incubations under identical conditions but in the absence of C-1305 did not lead to a significant loss of CYP activities. These results suggested that NADPH-dependent



metabolic activation of C-1305 to reactive intermediate by CYP1A2 or CYP3A4 was required for enzyme inactivation, though in the absence of NADPH a low level of inhibition was still observed.

#### ***Attenuation of C-1305-mediated inactivation of human recombinant CYP1A2 and CYP3A4 by a CYP-specific substrate***

In order to determine whether CYP1A2 or CYP3A4 inactivation by C-1305 was protected by the presence of a competing CYP substrate, 7-ethoxycoumarin and testosterone, respectively, varying concentrations of a CYP-specific substrate were preincubated with C-1305, human recombinant CYP isoform, and NADPH at 37°C for varying lengths of time. 7EC or TT at concentrations of 20, 40, and 80 µM corresponded to a molar ratio of 7EC (TT) to C-1305 of 1, 2 and 4, respectively. Our results indicated that both substrates reduced the ability of C-1305 to inactivate CYP1A2 or CYP3A4, what is illustrated in Figure 5. The remaining CYP1A2 activity in samples where C-1305 was co-incubated with 7EC at a molar ratio of 1:4 increased 48±2.8% in comparison to 7EC-free incubations after 60 min of preincubation (Figure 5A). In turn, C-1305 decreased the activity of CYP3A4 to 28±0.9% in TT-free incubations after 60 min of preincubation, and increasing concentrations of TT attenuated the extent of inactivation (Figure 5B). The obtained results indicated that 7EC and TT compete with C-1305 for metabolism by CYP1A2 and CYP3A4 isoforms, respectively, and thereby protect against inactivation. They also suggested that the inactivation of CYP1A2 or CYP3A4 proceeded via the attachment of C-1305 reactive intermediate to the active site of the enzyme.

#### ***Lack of GSH and catalase effects on inactivation of human recombinant CYP1A2 and CYP3A4 by C-1305***

To evaluate whether CYP1A2 and CYP3A4 inactivation by C-1305 was confined to the active site, the drug was preincubated with human recombinant CYP isoform and NADPH at 37°C for varying lengths of time in the presence or absence of a nucleophilic trapping agent (glutathione) or a scavenger of reactive oxygen species (catalase). As shown in Figure 6A, C-1305 alone decreased 7-ethoxycoumarin O-deethylation to 36±0.4% and testosterone 6β-

hydroxylation to  $36\pm 3.9\%$  after 60 min of preincubation, but the addition of GSH (1, 2, and 5 mM) did not attenuate the inactivation of CYP1A2 by C-1305 and had only a very little (~6%) protective effect against CYP3A4 inactivation by the TA. Similarly, catalase (1000 and 2000 U/mL) did not protect CYP1A2 and CYP3A4 against the inactivation by C-1305 (Figure 6B).

#### ***Irreversibility of human recombinant CYP1A2 and CYP3A4 inactivation by C-1305***

To examine whether the inactivation of CYP1A2 and CYP3A4 by C-1305 was irreversible, the studied drug was preincubated with human recombinant CYP isoform and NADPH at 37°C for 30 min before an aliquot was subjected to potassium ferricyanide for 15 min. These samples were also compared with that lacked potassium ferricyanide. Figure 7 shows that, as expected, the addition of potassium ferricyanide to the inactivation mixture did not affect the magnitude of the enzymes' inactivation significantly.

#### ***Partition ratio for the inactivation of human recombinant CYP1A2 and CYP3A4 by C-1305***

Given that C-1305 inactivated human recombinant CYP1A2 and CYP3A4 isoforms, we determined, in the next step, the partition ratio for the C-1305-mediated CYP1A2 and CYP3A4 inactivation. The partition ratio  $P$ , is defined as the number of inactivator molecules metabolized per molecule of enzyme inactivated (Hollenberg et al. 2008). It was estimated graphically using the method described previously (Silverman 1996; Kent et al. 1998). CYP isoform was incubated with various concentrations of C-1305, and the inactivation was allowed to progress for 60 min, until it was essentially complete. The percentage of remaining activity was plotted as a function of the molar ratio of C-1305 to CYP. The turnover number ( $P+1$ ) was estimated from the intercept of the linear regression line obtained from lower ratios of C-1305 to CYP and with the straight line derived from the higher ratios of C-1305 to CYP (Figure 8). With this method, we estimated the turnover numbers of ~1087 (CYP1A2) and ~198 (CYP3A4), and, consequently, the  $P$ s were ~1086 and ~197, respectively.



## Discussion

The results of the previous studies on the biologic and biochemical mechanisms of C-1305 action makes the compound very attractive as a potent anti-tumour agent for clinical development. In a separate study, we demonstrated that, contrary to the majority of therapeutic agents, C-1305 was not metabolized by the main CYP families, CYP1, CYP2 and CYP3. In contrast, C-1305 was determined to be a selective inhibitor of human (unpublished results) and rat liver microsomal, and human recombinant CYP1A2 and CYP3A4 isoenzymes (Fedejko-Kap et al. 2011), but the actual mechanism of the inhibition was not assessed. Thus, we undertook here to examine this issue, because C-1305, being a potent inhibitor of CYP1A2 and CYP3A4, might modulate the effectiveness of other drugs used in multidrug therapy.

The obtained results revealed that C-1305 is a mechanism-based inactivator of human recombinant CYP1A2 and CYP3A4 isoenzymes. It produced a time- and concentration-dependent inactivation of both enzymes. To more clearly define the inhibition potency of C-1305 against CYP1A2 and CYP3A4 the values of  $K_i$  and  $k_{inact}$  were determined (Figure 3, Table 1). The values of  $K_i$  (10.8 and 9.1  $\mu\text{M}$ ) indicated that this compound is a very potent inactivator of the studied CYP isoforms, although we observed the slightly different potential of C-1305 to inhibit both CYPs. The potency of CYP1A2 and CYP3A4 inactivation ( $K_i$ ) by C-1305 was similar to that for other inactivators, e.g., delavirdine (Voorman et al. 1998), raloxifene (Chen et al. 2002), and *trans*-resveratrol (Chang et al. 2001). The values of  $k_{inact}$  (0.016 and 0.022  $\text{min}^{-1}$ ) were lesser than other drugs, e.g., irinotecan (Hanioka et al. 2002), tamoxifen (Zhao et al. 2002), and dihydralazine (Masubuchi & Horie 1999). We also showed that a high level of inactivation was observed if NADPH was present in the incubation system (Figure 4). It strongly suggests that C-1305 itself is not an inactivator of CYP1A2 and CYP3A4, and that the loss of the catalytic activity of the enzymes requires metabolic activation of C-1305. A low level of inhibition was also observed in the absence of NADPH in a primary mixture. We suppose that NADPH added with the CYP-specific substrate in a secondary mixture could initiate the additional interactions between C-1305 and CYPs studied, and interactions of C-1305 with its metabolites. They were independent of the mechanism-based inactivation and could influence



the observed inhibition effect. The protective effect of 7-ethoxycoumarin on CYP1A2 and testosterone on CYP3A4 inactivation observed in a competing CYP-specific substrate experiments (Figure 5), indicates that C-1305 competed with 7-ethoxycoumarin or testosterone for the active site of the enzyme. As a result the generation of its reactive metabolites was diminished. These critical findings of substrate protection provide an evidence that bioactivation of C-1305 occurs in the active site of the enzyme.

Further evidence for the involvement of the CYP active site in the metabolic activation of C-1305 was provided by the observation that CYP1A2 and CYP3A4 inactivation was not protected by a nucleophilic trapping agent such as glutathione (exogenous nucleophile) (Figure 6A). This implies in part that CYP1A2 and CYP3A4 are covalently modified by electrophilic metabolites of C-1305 before escaping from the active site. Additionally, catalase, a scavenger of reactive oxygen species, did not prevent CYP1A2 and CYP3A4 inactivation induced by C-1305, suggesting that reactive oxygen species (*i.e.*, hydrogen peroxide, superoxide anion) were not involved in the inactivation event (Figure 6B). We also considered that mechanism-based enzyme inactivators are often irreversible inhibitors. Irreversibility of inactivation was evaluated here by oxidation with potassium ferricyanide. Activities of both CYP isoforms could not be recovered by potassium ferricyanide, which indicated the irreversible nature of inhibition (Figure 7).

In sum, C-1305 fulfilled the criteria for a mechanism-based inhibitor (Silverman 1996; Kalgutkar et al. 2007; Hollenberg et al. 2008). The results obtained in the present study gave a good support for earlier suggestions about the existence of a catalysis-dependent inactivation of CYPs upon oxidation of C-1305 to a reactive intermediate. The mechanism-based inactivation (MBI) of CYPs has been reported earlier for several therapeutic agents, including anti-tumour drugs such as thioTEPA (Richter et al. 2005), tamoxifen (Sridar et al. 2002; Zhao et al. 2002), and irinotecan (Hanioka et al. 2002).

The partition ratio gives an idea of the efficiency of the inactivator. We demonstrated that C-1305, with an estimated  $P$  value of 197, is a moderately efficient inactivator of CYP3A4, and it is much stronger than CYP1A2, which has a  $P$  value of 1087 (Figure 8). This finding allows



us to presume that C-1305-mediated inhibition of CYP1A2 and CYP3A4 activities may take place in slightly different ways. The differences in the strength of inhibition may result from the binding of an inhibitor in different pockets of the active sites of the two CYPs studied. On the other hand, the different structures and properties of the CYP1A2 and CYP3A4 active centers should be considered. Specifically, the CYP1A2 active site is opened directly above the set of four pyrrole rings of heme, while one of the pyrrole rings is protected by a protein helix in CYP3A4 and many other CYP isoforms. Thus, a larger and flexible active site of CYP3A4 enables interactions with substrates far from the heme and may take different spatial conformations depending on the type of the substrate. This ability would explain a wide range of substrate specificities of this isoenzyme (De Groot & Ekins 2002; Sevrioukova & Poulos 2013). It is also possible that, aside from the main mechanism of MBI, additional interactions between C-1305 and CYP (mainly CYP1A2) can influence the observed inhibition effect. These include reversible inhibition of CYP by C-1305 and its metabolites, and interactions of C-1305 with its metabolites.

Cytochrome P450 isoenzymes have been proposed as one of the targets of the reactive intermediates (Kalgutkar et al. 2007; Macherey & Dansette 2008). The precise mechanism by which C-1305 is transformed by CYP1A2 or CYP3A4 into a reactive intermediate, which inactivates the enzyme, remains unknown. MBI of CYPs by drugs can be due to the chemical modification of the heme or the apoprotein in a manner that destroys heme function or binding (Ortiz de Montellano & Correia 1995; Kalgutkar et al. 2007). The structure of C-1305 molecule strongly suggests that CYPs could catalyse hydroxylation of the aromatic ring or dealkylation of dialkylaminoalkyl side chain, as it has previously been confirmed for a number of drugs with a triazole moiety like anastrozole (Grimm & Dyroff 1997) and azamulin (Stresser et al. 2004), and with a diaminoalkyl side chain like fluoxetine (Murray & Murray 2003).

We suspect that the inhibitory effect of C-1305 on CYP monooxygenases may operate by several mechanisms. Some of the observations give a strong suggestion that CYP-mediated oxidation of the compound phenyl ring would lead to the formation of unstable epoxide intermediate (Potęga, unpublished results). The resulting epoxide metabolite may be further



transformed to electrophilic diol or *ortho*-quinone derivatives, which can react with nucleophilic groups on macromolecules or conjugate with GSH (Fontana et al. 2005). On the other hand, the primary amines, from CYP-mediated N-demethylation of C-1305 may also be related to C-1305 toxicity. Further studies are suggested to determine the potential reactive intermediates responsible for the inactivation of CYP1A2 and CYP3A4 by anti-tumour TA. The probable similarity in mechanism of CYP1A2 and CYP3A4 inactivation by two TAs, C-1305 and C-1299, with different substituents at the 8C on the phenyl ring, indicates that this structural element is presumably not responsible for the inactivation of CYP isoenzymes, which should be emphasized.

It is interesting to add that C-1305 was shown earlier to be a selective agonist of pregnane X receptor (PXR) (Niemira et al. 2013). Given that both PXR and CYP3A4 have a large, hydrophobic, and flexible ligand-binding domain (Hosea et al. 2000; Ekins et al. 2009), it is possible that a ligand of PXR may be also a substrate, direct inhibitor, or mechanism-based inactivator of CYP3A4. Our current findings indicated that C-1305, which is a PXR agonist, inactivated CYP3A4, thereby giving rise to the opposing effects on the catalytic activity of the enzyme. Such dual and opposing effects of activating PXR and inhibiting CYP3A4 activity were known earlier for ritonavir (Luo et al. 2002) and meclizine (Foo et al. 2015).

## Conclusions

In the present *in vitro* study, we demonstrated the existence of specific interactions between C-1305 and/or its metabolites, and human recombinant CYP1A2 and CYP3A4, which led to a decrease in the isoenzyme activities. A major conclusion is that the C-1305-mediated inactivation of CYP1A2 and CYP3A4 exhibits a number of characteristics consistent with mechanism-based inactivation. This work opens new avenues for understanding the mechanism of bioactivation and cytotoxicity induced by this anticancer compound. Our findings indicate that pharmacokinetic interactions between C-1305 and the substrates of CYP1A2 or CYP3A4 are likely to occur, which should be carefully considered in the optimal chemotherapy schedules designed for individual patients. Considering pharmacological aspect, inhibitory effect of C-1305 on CYP1A2 and CYP3A4 activity gives also the possibility for planning effective anti-tumour therapy in patients with genetic polymorphisms in CYP genes.

## **Acknowledgements**

Financial support from the National Science Center (Poland) [Grant N N405 127340 and Grant 2012/07/D/NZ7/03395] is gratefully acknowledged.

## **Declaration of interest statement**

The authors confirm that this article content has no conflicts of interest.

## References

Augustin E, Moś-Rompa A, Skwarska A, Witkowski JM, Konopa J. (2006). Induction of G2/M phase arrest and apoptosis of human leukemia cells by potent antitumor triazoloacridinone C-1305. *Biochem Pharmacol* 72:1668-1679.

Bibi Z. (2008). Role of cytochrome P450 in drug interactions. *Nutrition & Metabolism* 5:27.

Chang TK, Chen J, Lee WB. (2001). Differential inhibition and inactivation of human CYP1 enzymes by trans-resveratrol: evidence for mechanism-based inactivation of CYP1A2. *J Pharmacol Exp Ther* 299: 874-882.

Chen Q, Ngui JS, Doss GA, Wang RW, Cai X, DiNinno FP, Blizzard TA, Hammond ML, Stearns RA, Evans DC, Baillie TA, Tang W. (2002). Cytochrome P450 3A4-mediated bioactivation of raloxifene: irreversible enzyme inhibition and thiol adduct formation. *Chem Res Toxicol* 15:907-914.

Cholody WM, Martelli S, Konopa J. (1990a). 8-Substitued 5-[(aminoalkyl)amino]-6H-v-triazolo[4,5,1-de]acridin-6-ones as potential antineoplastic agents. Synthesis and biological activity. *J Med Chem* 33:2852-2856.

De Groot MJ, Ekins S. (2002). Pharmacophore modeling of cytochromes P450. *Adv Drug Deliv Rev* 54:367-383.

Dziegielewski J, Konopa J. (1996). Interstrand crosslinking of DNA induced in tumor cells by a new group of antitumor imidazoacridinones. *Proc Am Assoc Cancer Res* 37:410.



Dziegielewski J, Slusarski B, Konitz A, Skladanowski A, Konopa J. (2002). Intercalation of imidazoacridinones to DNA and its relevance to cytotoxic and antitumor activity. *Biochem Pharmacol* 63:1653-1662.

Ekins S, Kortagere S, Iyer M, Reschly EJ, Lill MA, Redinbo MR, Krasowski MD. (2009). Challenges predicting ligand–receptor interactions of promiscuous proteins: the nuclear receptor PXR. *PLoS Comput Biol* 5:1-37.

Fedjko-Kap B, Niemira M, Radomska-Pandya A, Mazerska Z. (2011). Flavin monooxygenases, FMO1 and FMO3, not cytochrome P450 isoenzymes, contribute to metabolism of anti-tumour triazoloacridinone, C-1305, in liver microsomes and HepG2 cells. *Xenobiotica* 41:1044-1055.

Fedjko-Kap B, Bratton SM, Finel M, Radomska-Pandya A, Mazerska Z. (2012). The role of human UDP-glucuronosyltransferases in the biotransformation of the triazoloacridinone and imidazoacridinone antitumor agents C-1305 and C-1311: highly selective substrates for UGT1A10. *Drug Metab Dispos* 40:1736-1743.

Fontana E, Dansette PM, Poli SM. (2005). Cytochrome P450 enzymes mechanism based inhibitors: common sub-structures and reactivity. *Curr Drug Metab* 6:413-454.

Foo WY, Tay HY, Chan EC, Lau AJ. (2015). Meclizine, a pregnane X receptor agonist, is a direct inhibitor and mechanism-based inactivator of human cytochrome P450 3A. *Biochem Pharmacol* 97:320-330.

Grimm SW, Dyroff MC. (1997). Inhibition of human drug metabolizing cytochromes P450 by anastrozole, a potent and selective inhibitor of aromatase. *Drug Metab Dispos* 25:598-602.

Guengerich FP. (1995). Human cytochrome P450 enzymes. In: Ortiz de Montellano PR, ed. Cytochrome P450 Structure Mechanism and Biochemistry. New York, NY: 2nd ed. Plenum Press, 473-535.

Guengerich FP. (1999). Cytochrome P450 3A4: regulation and role in drug metabolism. *Annu Rev Pharmacol Toxicol* 39:1-17.

Hanioka N, Ozawa S, Jinno H, Tanaka-Kagawa T, Nishimura T, Ando M, Sawada Ji J. (2002). Interaction of irinotecan (CPT-11) and its active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38) with human cytochrome P450 enzymes. *Drug Metab Dispos* 30:391-396.

Hollenberg PF, Kent UM, Bumpus NN. (2008). Mechanism-based inactivation of human cytochromes p450s: experimental characterization, reactive intermediates, and clinical implications. *Chem Res Toxicol* 21:189-205.

Hosea NA, Miller GP, Guengerich FP. (2000). Elucidation of distinct ligand binding sites for cytochrome P450 3A4. *Biochemistry* 39:5929-5939.

Kalgutkar AS, Obach RS, Maurer TS. (2007). Mechanism-based inactivation of cytochrome P450 enzymes: chemical mechanisms, structure-activity relationships and relationship to clinical drug-drug interactions and idiosyncratic adverse drug reactions. *Curr Drug Metab* 8:407-447.

Kent UM, Roberts ES, Chun J, Hodge K, Juncaj J, Hollenberg PF. (1998). Inactivation of cytochrome P450 E1 by tert-butylisothiocyanate. *Chem Res Toxicol* 11:1154-1161.

Kitz R, Wilson IB. (1962). Esters of methanesulfonic acid as irreversible inhibitors of acetylcholinesterase. *J Biol Chem* 237:3245-3249.





Kivisto KT, Kroemer HK, Eichelbaum M. (1995). The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions. *Br J Clin Pharmacol* 40:523-530.

Koba M, Konopa J. (2007). Interactions of antitumor triazoloacridinones with DNA. *Acta Biochim Pol* 54:297-306.

Kusnierczyk H, Cholody WM, Paradziej-Lukowicz J, Radzikowski C, Konopa J. (1994). Experimental antitumor activity and toxicity of the selected triazolo- and imidazoacridinones. *Arch Immunol Ther Exper (Warsz)* 42:415-423.

Lemke K, Wojciechowski M, Laine W, Bailly C, Colson P, Baginski M, Larsen AK, Skladanowski A. (2005). Induction of unique structural changes in guanine-rich DNA regions by the triazoloacridone C-1305, a topoisomerase II inhibitor with antitumor activities. *Nucleic Acids Res* 33:6034-6047.

Luo G, Cunningham M, Kim S, Burn T, Lin J, Sinz M, Hamilton G, Rizzo C, Jolley S, Gilbert D, Downey A, Mudra D, Graham R, Carroll K, Xie J, Madan A, Parkinson A, Christ D, Selling B, LeCluyse E, Gan LS. (2002). CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. *Drug Metab Dispos* 30:795-804.

Macherey AC, Dansette PM. (2008). Biotransformations leading to toxic metabolites: chemical aspect. In: Wermuth CG, ed. *The Practice of Medicinal Chemistry*. Oxford, UK: Academic Press, 674-696.



Masubuchi Y, Horie T. (1999). Mechanism-based inactivation of cytochrome P450s 1A2 and 3A4 by dihydralazine in human liver microsomes. *Chem Res Toxicol* 12:1028-1032.

Murray M, Murray K. (2003). Mechanism-based inhibition of CYP activities in rat liver by fluoxetine and structurally similar alkylamines. *Xenobiotica* 10:973-987.

Niemira M, Dastyk J, Mazerska Z. (2013). Pregnane X receptor dependent up-regulation of CYP2C9 and CYP3A4 in tumor cells by antitumor acridine agents, C-1748 and C-1305, selectively diminished under hypoxia. *Biochem Pharmacol* 86:231-241

Ortiz de Montellano PR, Correia MA. (1995). Inhibition of cytochrome P450. In: Ortiz de Montellano PR, ed. *Cytochrome P450 structure, mechanism and biochemistry*. New York, NY: Plenum Press, 305-366.

Pawlowska M, Chu R, Fedejko-Kap B, Augustin E, Mazerska Z, Radomska-Pandya A, Chambers TC. (2012). Metabolic transformation of antitumor acridinone C-1305 but not C-1311 via selective cellular expression of UGT1A10 increases cytotoxic response: implications for clinical use. *Drug Metab Dispos* 41:414-421.

Richter T, Schwab M, Eichelbaum M, Zanger UM. (2005). Inhibition of human CYP2B6 by N,N', N''-triethylenethiophosphoramidate is irreversible and mechanism-based. *Biochem Pharmacol* 69:517-524.

Sevrioukova IF, Poulos TL. (2013). Understanding the mechanism of cytochrome P450 3A4: recent advances and remaining problems. *Dalton Trans* 42:3116-3126.

Silverman RB. (1996). Mechanism-based enzyme inactivation. In: Purich DL, ed. *Contemporary Enzyme Kinetics and Mechanisms*. San Diego, CA: Academic Press, 291-335.



Skladanowski A, Plisov SY, Konopa J, Larsen AK. (1996). Inhibition of DNA topoisomerase II by imidazoacridinones, new antineoplastic agents with strong activity against solid tumors. *Mol Pharmacol* 49:772-80.

Sridar C, Kent UM, Notley LM, Gillam EM, Hollenberg PF. (2002). Effect of Tamoxifen on the Enzymatic Activity of Human Cytochrome CYP2B6. *J Pharmacol Exp Ther* 301:945-952.

Stresser DM, Broudy MI, Ho T, Cargill CE, Blanchard AP, Sharma R, Dandeneau AA, Goodwin JJ, Turner SD, Erve JC, Patten CJ, Dehal SS, Crespi CL. (2004). Highly selective inhibition of human CYP3Aa *in vitro* by azamulin and evidence that inhibition is irreversible. *Drug Metab Dispos* 32:105-112.

Venkatakrishnan K, Rostami-Hodjegan A. (2007). Mechanism-based inactivation of human cytochrome P450 enzymes: strategies for diagnosis and drug-drug interaction risk assessment. *Xenobiotica* 37:1225-1256.

Voorman RL, Maio SM, Hauer MJ, Sanders PE, Payne NA, Ackland MJ. (1998). Metabolism of delavirdine, a human immunodeficiency virus type-1 reverse transcriptase inhibitor, by microsomal cytochrome P450 in humans, rats, and other species: probable involvement of CYP2D6 and CYP3A. *Drug Metab Dispos* 26:631-639.

Yamazaki H, Inoue K, Mimura M, Oda Y, Guengerich FP, Shimada T. (1996). 7-Ethoxycoumarin O-deethylation catalysed by cytochromes P450 1A2 and 2E1 in human liver microsomes. *Biochem Pharmacol* 51:313-319.

Yuan R, Madani S, Wei XX, Reynolds K, Huang SM. (2002). Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study *in vitro* drug interactions. *Drug Metab Dispos* 30:1311-1319.



Zhao XJ, Jones DR, Wang YH, Grimm SW, Hall SD. (2002). Reversible and irreversible inhibition of CYP3A enzymes by tamoxifen and metabolites. *Xenobiotica* 32:863-878.

## Tables with captions

**Table 1**

Kinetic parameters for the inactivation of 7-ethoxycoumarin O-deethylation (CYP1A2) and 6 $\beta$ -testosterone hydroxylation (CYP3A4) activities by C-1305.

Inhibitor	Kinetic parameters of CYP-specific reactions					
	7-Ethoxycoumarin O-deethylation (CYP1A2)			Testosterone 6 $\beta$ -hydroxylation (CYP3A4)		
	$K_i$ [ $\mu$ M]	$k_{inact}$ [min <sup>-1</sup> ]	$t_{1/2inact}$ [min]	$K_i$ [ $\mu$ M]	$k_{inact}$ [min <sup>-1</sup> ]	$t_{1/2inact}$ [min]
<b>C-1305</b>	10.8 $\pm$ 2.14	0.016 $\pm$ 0.0015	43.3 $\pm$ 4.09	9.1 $\pm$ 2.82	0.022 $\pm$ 0.0031	31.5 $\pm$ 4.53

The presented values of kinetic parameters were calculated using GraphPad Prism 6.05 (GraphPad Software, Inc., San Diego, CA) and are based on the data shown in Figure 3.  $K_i$ : the concentration required for half-maximum inactivation;  $k_{inact}$ : the maximum rate of inactivation at saturation;  $t_{1/2inact}$ : inactivation half-life.

## Figure captions

### Figure 1

Chemical structures of anti-tumour triazoloacridinones, C-1305 and C-1299.

### Figure 2

Scheme of mechanism-based inactivation experiments.

### Figure 3

Time- and concentration-dependent inactivation of 7-ethoxycoumarin O-deethylation (CYP1A2) (**A**) and testosterone 6 $\beta$ -hydroxylation (CYP3A4) (**B**) activities by C-1305. Assay conditions were described in Materials and methods section. The concentrations of C-1305 were: (■) 0, (◆) 5, (□) 10, (▲) 25, (△) 50, and (◇) 100  $\mu$ M. The insets show corresponding Kitz-Wilson plots (the inverse of the observed inactivation rate constant,  $1/k_{obs}$ , versus the inverse of C-1305 concentration). Each point represents the mean  $\pm$  SD for three independent experiments. The  $K_I$ ,  $k_{inact}$  and  $t_{1/2inact}$  values are shown in Table 1.

### Figure 4

Effect of NADPH on inactivation of human recombinant CYP1A2 (**A**) and CYP3A4 (**B**) by C-1305. Assay conditions were described in Materials and methods section. The concentrations of C-1305 were: 5, 10, 20, 50, and 100  $\mu$ M. Data are normalized to the enzymatic activity of the C-1305-free control incubations and expressed as the mean  $\pm$  SD for three independent experiments. Comparisons were made using two-way ANOVA followed by Bonferroni's multiple comparisons test. \*Indicates significance of 0.5 or 1 mM NADPH results with respect to no NADPH results at the same preincubation time. Levels were considered significant at \*\*\*\* $p < 0.0001$ , \*\*\* $p < 0.001$ , \*\* $p < 0.01$ , and \* $p < 0.05$ ; ns, not significant.

### Figure 5

Substrate protection against inactivation of human recombinant CYP1A2 (**A**) and CYP3A4 (**B**) by C-1305. Assay conditions were described in Materials and methods section. Aliquots were removed from the primary reaction mixture at the indicated time points and assayed for remaining enzyme activity in a secondary incubation mixture. The primary reaction mixtures



contained the following molar ratios of C-1305 to 7EC (TT): (■) 1:0, (◆) 1:1, (□) 1:2, and (△) 1:4. Each point represents the mean  $\pm$  SD for three independent experiments.

### Figure 6

Effects of glutathione (GSH) (**A**) and catalase (CAT) (**B**) on inactivation of human recombinant CYP1A2 and CYP3A4 by C-1305. Assay conditions were described in Materials and methods section. Each point represents the mean  $\pm$  SD for three independent experiments.

### Figure 7

Effect of potassium ferricyanide on inactivation of human recombinant CYP1A2 and CYP3A4 by C-1305. Assay conditions were described in Materials and methods section. Data are normalized to the enzymatic activity of the vehicle-treated control group that was not subjected to preincubation and expressed as the mean  $\pm$  SD for three independent experiments. Comparisons were made using an unpaired *t*-test. \*Indicates significance of 0.5 mM NADPH results with respect to no NADPH results at the same incubation time. Levels were considered significant at \*\*\*\* $p < 0.0001$  and \*\*\* $p < 0.001$ .

### Figure 8

Partition ratio for the inactivation of human recombinant CYP1A2 (**A**) and CYP3A4 (**B**) by C-1305. Assay conditions were described in Materials and methods section. The extrapolated partition ratio (P) was estimated from the intercept of the linear regression line from the lower ratios, and the straight line was obtained from higher ratios. Data are normalized to the enzymatic activity of the C-1305-free control incubations and expressed as the mean  $\pm$  SD for three independent experiments.

**Figure 1**






Figure 2




Figure 3




Figure 4




Figure 5




Figure 6




Figure 7




Figure 8

